Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with the precarious case of gene therapy in Europe, a long-awaited coup for Novavax, and the unwinding of Amgen’s success story.
The need-to-know this morning
• Sanofi will spend up to $1.5 billion to co-develop and co-commercialize Teva’s experimental arthritis drug as a treatment for inflammatory bowel disease.
• Eli Lilly announced a reshuffling of its leadership, including promoting David Hyman to chief medical officer.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.